Dr. Kalinsky on Ruxolitinib Plus Trastuzumab in HER2-Positive Breast Cancer

Kevin Kalinsky, MD
Published Online: Wednesday, Jan 11, 2017



Kevin Kalinsky, MD, assistant professor of Medicine at Columbia University Medical Center, discusses a phase I study of ruxolitinib (Jakafi) in combination with trastuzumab (Herceptin) in metastatic HER2-positive breast cancer.

Ruxolitinib, a JAK2 inhibitor, was given in combination with trastuzumab to patients who have progressed on trastuzumab. This non-chemotherapy regimen is taken orally, familiar to patients previously who were treated with trastuzumab.

Results showed the combination was well tolerated without any observable toxicities. A multi-centered phase II trial is ongoing.
 


Kevin Kalinsky, MD, assistant professor of Medicine at Columbia University Medical Center, discusses a phase I study of ruxolitinib (Jakafi) in combination with trastuzumab (Herceptin) in metastatic HER2-positive breast cancer.

Ruxolitinib, a JAK2 inhibitor, was given in combination with trastuzumab to patients who have progressed on trastuzumab. This non-chemotherapy regimen is taken orally, familiar to patients previously who were treated with trastuzumab.

Results showed the combination was well tolerated without any observable toxicities. A multi-centered phase II trial is ongoing.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group to Advance the Treatment of Triple-Negative Breast Cancer: Examining the Evidence and Looking to the FutureFeb 28, 20171.5
Clinical Vignette Series: 33rd Annual Miami Breast Cancer Conference®May 18, 20172.0
Publication Bottom Border
Border Publication